Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears SQI Diagnostics' Platform, Test for Celiac Disease

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian life science firm SQI Diagnostics today announced that the US Food and Drug Administration has cleared its SQIDworks platform and IgXPlex celiac qualitative assay.

The 4-plex microarray-based assay tests for anti-tissue transglutaminase IgG and IgA and is the second multiplexed assay cleared by the FDA to run on the SQIDworks platform, after clearance of SQI's IgXplex rheumatoid arthritis assay in late 2009.

The celiac assay previously received regulatory approval in Canada and CE marking in Europe.

Based in Toronto, SQI is developing a 6-plex quantitative celiac panel for the US market, which will include quantitative determinations of IgA and IgG anti-gliadin antibodies, IgA and IgG anti-tissue transglutaminase antibodies, and IgA and IgG anti-deamidated gliadin peptide antibodies, it said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.